Primary hyperparathyroidism is a versatile condition, so how can you keep up? Here are three clinical pearls to keep in mind when seeing a patient with PHPT.
The GLP-1 receptor agonist/metformin combination did not support weight loss in this population but did increase pregnancy rates per in vitro embryo transfer.
Empagliflozin shown to significantly reduce liver fat in patients with T2DM, according to a new study.
In a new study, the GLP-1 receptor agonist semaglutide was associated with greater weight loss than placebo -- and liraglutide.
A high-energy breakfast diet may be an effective strategy to improve diabetes control, according to a new study.
Three new diabetic technologies have been approved by the FDA. What are they? Scroll through our slideshow to find out.
A patch that can detect early symptoms of hypoglycemia is one of three studies discussed in this month's endocrinology news roundup.
From degludec to dulaglutide, we’ve come a long way from the years when there was only one option to treat type 2 diabetes. Here's a look at metformin's place in this history.
Fasting sounds like a bad idea for anyone with type 2 diabetes and especially bad for someone taking antihyperglycemic drugs. But, is it really?
Endonet enl for Wed 3-14-18
Subject line: Smart Contacts: A Close Look at Real-time Glucose Levels
Preheader: Plus: Keeping Diabetes Patients Safe This Flu Season
The ability to monitor glucose levels quite literally with the blink of an eye has gotten one step closer to clinical application. Get a quick review.
The influenza virus can be debilitating for your diabetes patients for many reasons. Here are some tips to help you help them stay safe this year.
Carb counting, bar-code recognition, log-book, exercise tracker, insulin calculator -- and more, all in each one of these 5 apps.
Three new diabetes studies highlight one risk, one potential prevention, and one possible new treatment.